The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1372
Screening for Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body examination for melanoma and other skin cancers.1

HIGH-RISK GROUPS — Patients with red hair, fair skin, numerous freckles and light eyes, a family history of melanoma, a personal history of non-melanoma skin cancer, atypical moles or many moles (>50) have an increased risk of developing melanoma. Elderly men have a higher risk of developing melanoma than younger men or women of any age; white men >50 years old are the most likely to have rapidly growing melanomas.2

DETECTION — Melanoma detected early is associated with prolonged disease-free survival. Late detection is associated with death from metastatic disease. Most ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Screening for Melanoma
Article code: 1372c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian